These experimental results suggest that adiponectin is decreased in obesity leading to the onset of insulin resistance and the metabolic syndrome, while adiponectin supplementation represents an effective therapeutic option for the metabolic syndrome associated with obesity. The gene discussed is ADIPOQ; the disease is Insulin resistance.